Robert C. Flanigan
M.D.
Albert J. and Claire R. Speh Professor of Urology
Department Chairperson, Urology
Urology
CONTACT INFORMATION
Specialties
Bladder Cancer, Kidney Cancer, Testicular Cancer, Kidney Transplant, Prostate Cancer
Board Certifications
Urology - General Cert: AM Board of Urology
Publications
Prognostic variables and nomograms for renal cell carcinomaFlanigan,R. C.; Polcari,A. J.; Hugen,C. M.INTERNATIONAL JOURNAL OF UROLOGY 2011 ;18(1):20-31
The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function.Mulhall,J. P.; Parker,M.; Waters,B. W.; Flanigan,R. C.BJU INTERNATIONAL 2010 ;105(1):37-41
Risk factors for recurrence following radical cystectomy for pathologic node negative bladder cancer.Hugen,C. M.; Polcari,A. J.; Fitzgerald,M. P.; Dauw,C.; Flanigan,R. C.; Quek,M. L.JOURNAL OF SURGICAL ONCOLOGY 2010 ;102(4):334-337
Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram.Hugen,C. M.; Polcari,A. J.; Quek,M. L.; Garza,R. P.; Fitzgerald,M. P.; Flanigan,R. C.WORLD JOURNAL OF UROLOGY 2010 ;28(6):741-744
Morphometric signature differences in nuclei of Gleason pattern 4 areas in Gleason 7 prostate cancer with differing primary grades on needle biopsy.Venkataraman,G.; Rycyna,K.; Rabanser,A.; Heinze,G.; Baesens,B. M.; Ananthanarayanan,V.; Paner,G. P.; Barkan,G. A.; Flanigan,R. C.; Wojcik,E. M.JOURNAL OF UROLOGY 2009 ;181(1):88-93
Persistent erectile dysfunction following radical prostatectomy: the association between nerve-sparing status and the prevalence and chronology of venous leak.Tal,R.; Valenzuela,R.; Aviv,N.; Parker,M.; Waters,W. B.; Flanigan,R. C.; Mulhall,J. P.JOURNAL OF SEXUAL MEDICINE 2009 ;6(10):2813-2819
Is microscopic evaluation of hilar fat necessary in renal cell carcinoma?Fok,C. S.; Ghai,R.; Quek,M. L.; Flanigan,R. C.; Picken,M. M.JOURNAL OF UROLOGY 2009 ;181(4):248
Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.Lara,P. N.,Jr; Tangen,C. M.; Conlon,S. J.; Flanigan,R. C.; Crawford,E. D.JOURNAL OF UROLOGY 2009 ;181(2):512-516
Inaugural core curriculum for urologyFlanigan,R. C. 2009 ; ( ):
Words of wisdom. Re: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.Flanigan,R. C.; Polcari,A.EUROPEAN UROLOGY 2009 ;55(4):990-991
The role of lymph node density in bladder cancer prognosticationQuek,M. L.; Flanigan,R. C.WORLD JOURNAL OF UROLOGY 2009 ;27(1):27-32
The role of cytoreductive nephrectomy in the era of molecular targeted therapyPolcari,A. J.; Gorbonos,A.; Milner,J. E.; Flanigan,R. C.INTERNATIONAL JOURNAL OF UROLOGY 2009 ;16(3):227-233
Comparison of open and robot-assisted pelvic lymphadenectomy for prostate cancer.Polcari,A. J.; Hugen,C. M.; Sivarajan,G.; Woods,M. E.; Paner,G. P.; Flanigan,R. C.; Quek,M. L.JOURNAL OF ENDOUROLOGY 2009 ;23(8):1313-1317
Glucose Regulated Protein-78 (GRP78) Expression in Urothelial Carcinoma: A Potential Marker for Chemotherapy ResistanceGorbonos,A.; Knesek,M.; Barkan,G. A.; Paner,G. P.; Woods,M.; Flanigan,R. C.; Quek,M. L.USCAP Annual Meeting 2009 ; ( ):
The 5-minute urology consultGomella,L. G.; Flanigan,R. C. 2009 ; ( ):834-834
Renal FNA-based typing of renal masses remains a useful adjunctive modality: evaluation of 31 renal masses with correlative histology.Masoom,S.; Venkataraman,G.; Jensen,J.; Flanigan,R. C.; Wojcik,E. M.CYTOPATHOLOGY 2009 ;20(1):50-55
Renal cell carcinoma in two patients with crossed fused ectopic kidneys.Davis,C. M.; Rao,M. V.; Flanigan,R. C.; Quek,M. L.UROLOGIA INTERNATIONALIS 2008 ;81(3):370-372
Chromosome 1 analysis in chromophobe renal cell carcinomas with tissue microarray (TMA)-facilitated fluorescence in situ hybridization (FISH) demonstrates loss of 1p/1 which is also present in renal oncocytomas.Meyer,P. N.; Cao,Y.; Jacobson,K.; Krausz,T.; Flanigan,R. C.; Picken,M. M.DIAGNOSTIC MOLECULAR PATHOLOGY 2008 ;17(3):141-144
Nephrectomy in patients with metastatic renal cell carcinoma : clinical and biologic effectsOrris,B. G.; Flanigan,R. C. 2008 ; (Chapter 21):335-353
Analysis of chromosome 1p abnormalities in renal oncocytomas by loss of heterozygosity studies: correlation with conventional cytogenetics and fluorescence in situ hybridization.Picken,M. M.; Chyna,B.; Flanigan,R. C.; Lee,J. M.AMERICAN JOURNAL OF CLINICAL PATHOLOGY 2008 ;129(3):377-382
Comparison of lymph node yield between robotic-assisted and open pelvic lymphadenectomy for prostate cancerPelcari,A.; Fok,C.; Woods,M.; Flanigan,R. C.; Quek,M. L.Society of Urologic Cancer/National Cancer Institute Winter Meeting 2008 ; ( ):
High incidence of aneuploidy in low grade urothelial carcinomasAlvarez,A.; Venkataraman,G.; Quek,M.; Flanigan,R.; Wojcik,E.INTERNATIONAL JOURNAL OF UROLOGY 2008 ;15(3):279-279
The importance of histology and cytogenetics in decision making for renal cell carcinoma.Garcia,J. G.; Picken,M. M.; Flanigan,R. C.WORLD JOURNAL OF UROLOGY 2008 ;26(2):155-160
Maintenance of Certification: what is it and why is it happening.Flanigan,R. C.; Howards,S. S.AUA Update Series 2008 ;27( ):
Urine cytology for surveillance of the remnant urothelium after radical cystectomy and urinary diversionFok,C. S.; Liu,L.; Venkataraman,G.; Barkan,G. A.; Flanigan,R. C.; Wojcik,E. M.; Quek,M. L.JOURNAL OF UROLOGY 2008 ;179(4 Supplement):249
Prostate-specific antigen density (PSAD) versus prostate-specific antigen (PSA) in predicting biochemical recurrence following radical prostatectomyKadow,B. T.; Almoshelli,B.; Quek,M. L.; Branch,J. D.; Venkataraman,G.; Flanigan,R. C.Society of Urologic Cancer/National Cancer Institute Winter Meeting 2008 ; ( ):
Prostate specific antigen (PSA)-based screening.Suzuki,H.; Flanigan,R. C.; Okuyama,A.INTERNATIONAL JOURNAL OF UROLOGY 2008 ;15(9):757-762
Pathologic N-Stage, and Not Primary T-Stage Is a Significant Predictor of Relapse-Free Survival (RFS) in Bladder Cancer after Radical Cystectomy for Cancer: A Multivariate Cox Analysis in 247 Patients
Abstract # 119.Venkataraman,G.; Liu,L.; Masoom,S.; El-Salem,F.; Paner,G. P.; Barkan,D. S.; Subramaniiam,D. S.; Quek,M. L.; Flanigan,R. C.; Wojcik,E. M. 2008 ; ( ):
Abstract # 119.Venkataraman,G.; Liu,L.; Masoom,S.; El-Salem,F.; Paner,G. P.; Barkan,D. S.; Subramaniiam,D. S.; Quek,M. L.; Flanigan,R. C.; Wojcik,E. M. 2008 ; ( ):
Distinctive Morphometric Signatures Exist within Nuclei of Gleason Pattern 4 Areas in Gleason 7 Prostate Cancer with Differing Primary Grades on Needle Biopsy
Abstract # 195.Venkataraman,G.; Rycyna,K.; Ananthanarayanan,V.; Hutchens,K. A.; Paner,G. P.; Flanigan,R. C.; Wojcik,E. M. 2008 ; ( ):
Abstract # 195.Venkataraman,G.; Rycyna,K.; Ananthanarayanan,V.; Hutchens,K. A.; Paner,G. P.; Flanigan,R. C.; Wojcik,E. M. 2008 ; ( ):
Advanced Disease: Nonpulmonary MetastasesVoelzke,B. B.; Flanigan,R. C. 2008 ; (Chapter 8j):257-279
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.Wood,C.; Srivastava,P.; Bukowski,R.; Lacombe,L.; Gorelov,A. I.; Gorelov,S.; Mulders,P.; Zielinski,H.; Hoos,A.; Teofilovici,F.; Isakov,L.; Flanigan,R. C.; Figlin,R.; Gupta,R.; Escudier,B.LANCET 2008 ;372(9633):145-154
Pre-biopsy PSA and percentage of cancer on prostate biopsy can adequately predict upgrading of Gleason Score on subsequent prostatectomyVenkataraman,G.; Ryeyna,K.; Flanigan,R. C.; Wojcik,E. M. 2007 ; ( ):
Identification of patients with low-risk for aneuploidy: comparative discriminatory models using linear and machine-learning classifiers in prostate cancer.Venkataraman,G.; Heinze,G.; Holmes,E. W.; Ananthanarayanan,V.; Bostwick,D. G.; Paner,G. P.; Bradford-De La garza,C. M.; Brown,H. G.; Flanigan,R. C.; Wojcik,E. M.PROSTATE 2007 ;67(14):1524-1536
The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.Kositsawat,J.; Flanigan,R. C.; Meydani,M.; Choi,Y. K.; Freeman,V. L.JOURNAL OF UROLOGY 2007 ;178(6):2391-2396
Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: identification of predictive features using bootstrap method.Kapur,U.; Antic,T.; Venkataraman,G.; Durazo-Arvizu,R. A.; Quek,M. M.; Flanigan,R. C.; Wojcik,E. M.UROLOGY 2007 ;70(5):1028-1033
Management protocols for locally advanced and metastatic kidney cancerFlanigan,R. C.Reviews in Urology 2007 ;9(3):
Renal tumors: the good, the bad, and the uglyFlanigan,R. C.INTERNATIONAL JOURNAL OF UROLOGY 2007 ;14(7):575-580
Urothelial tumors of the upper urinary tractFlanigan,R. C. 2007 ;Vol. 2(Section XII, Chapter 48):1638-1652
Self-reported volume of radical prostatectomies among urologists in the USA.Denberg,T. D.; Flanigan,R. C.; Kim,F. J.; Hoffman,R. M.; Steiner,J. F.BJU INTERNATIONAL 2007 ;99(2):339-343
Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer.Freeman,V. L.; Flanigan,R. C.; Meydani,M.CANCER CAUSES & CONTROL 2007 ;18(2):211-218
Can lymphatic drainage from the kidney be predicted? Retrospective study based on 389 nephrectomies from a single institutionGhai,R.; Quek,M. L.; Flanigan,R. C.; Picken,M. M.United States & Canadian Academy of Pathology Annual Meeting 2007 ; ( ):
Vanishing prostate cancer on radical prostatectomy: incidence and follow-up data from a cohort of 850 patients between 1998-2006.Alvarez,A. I.; Venkataraman,G.; Ryeyna,G.; Flanigan,R. C.; Wojcik,E. M. 2007 ; ( ):
Xp11.2 translocation renal cell carcinoma in adult patientsFok,C. S.; Picken,M. M.; Meyer,P. N.; Clark,J. I.; Flanigan,R. C.; Quek,M. L.American Urological Association Annual Meeting 2007 ; ( ):
High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: cytogenetic and fluorescence in situ hybridization studies.Paner,G. P.; Lindgren,V.; Jacobson,K.; Harrison,K.; Cao,Y.; Campbell,S. C.; Flanigan,R. C.; Picken,M. M.ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 2007 ;131(1):81-85
Nephrectomy in patients with metastatic renal cell carcinoma: clinical and biologic effectsOrris,B.; Flanigan,R. C. 2007 ; (21):335-353
Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.Nagda,S. N.; Mohideen,N.; Lo,S. S.; Khan,U.; Dillehay,G.; Wagner,R.; Campbell,S.; Flanigan,R. C.International journal of radiation oncology, biology, physics 2007 ;67(3):834-840
Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults.Meyer,P. N.; Clark,J. I.; Flanigan,R. C.; Picken,M. M.AMERICAN JOURNAL OF CLINICAL PATHOLOGY 2007 ;128(1):70-79
Complications of open renal surgeryMcNeil,B.; Flanigan,R. C. 2007 ; (Chapter 6):65-80
Analysis of cases with abnormal urine cytology and normal histologic findings over a five year periodGorbonos,A.; Wojcik,E. M.; Jensen,J.; Flanigan,R. C.; Quek,M. L.American Urological Association Annual Meeting 2007 ; ( ):
Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells.Basrawala,Z.; Alimirah,F.; Xin,H.; Mohideen,N.; Campbell,S. C.; Flanigan,R. C.; Choubey,D.ONCOGENE 2006 ;25(19):2812-2817
The relationship between threat appraisal and social constraints in cancer survivors and their spouses.Herzer,M.; Zakowski,S. G.; Flanigan,R. C.; Johnson,P.Journal of Behavioral Medicine 2006 ;29(6):549-560
Fine needle aspiration (FNA) of the Kidney. Corcordance of cytologic typing/grading with histology in 31 renal masses. Abstract # 289.Masoom,S.; Venkataraman,G.; Jensen,J.; Flanigan,R. C.; Wojcik,E. M.LABORATORY INVESTIGATION 2006 ;86(1S):66A
Utility of prostate biopsy morphometric sum optical density for identifying extraprostatic extension on subsequent prostatectomy.Bargaje,A.; Venkataraman,G.; Flanigan,R. C.; Wojcik,E. M.; Ananthanarayanan,V.Analytical & Quantitative Cytology & Histology 2006 ;28(6):343-345
Urothelial-cell carcinoma and solitary kidney: outcomes with renal-sparing management.Milner,J. E.; Voelzke,B. B.; Flanigan,R. C.; Sharma,S. K.; Perry,K. T.; Turk,T. M.JOURNAL OF ENDOUROLOGY 2006 ;20(10):800-807
Radical cystectomy with extended lymphadenectomy in the presence of a pelvic kidney.Quek,M. L.; Basrawala,Z.; McClung,C.; Flanigan,R. C.UROLOGY 2006 ;68(3):672.e21-672.e22
Management of metastatic renal cell carcinoma : the role of surgeryFlanigan,R. C.; Orris,B. G. 2006 ; (Chapter 48A):767-772
Prognostic significance of positive ureteral margins at radical cystectomyKnesek,M. J.; Ouwenga,M. K.; Flanigan,R. C.; Quek,M. L.St. Albert's Day Graduate Research Forum 2006 ; ( ):
The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma.Denberg,T. D.; Kim,F. J.; Flanigan,R. C.; Fairclough,D.; Beaty,B. L.; Steiner,J. F.; Hoffman,R. M.MEDICAL CARE 2006 ;44(12):1137-1141
Subspecialty certification in urology: a US perspective.Flanigan,R. C.NATURE CLINICAL PRACTICE UROLOGY 2006 ;3(10):509
Morphometric sum optical density as a surrogate marker for ploidy status in prostate cancer: an analysis in 180 biopsies using logistic regression and binary recursive partitioning.Venkataraman,G.; Ananthanarayanan,V.; Paner,G. P.; He,R.; Masoom,S.; Sinacore,J.; Flanigan,R. C.; Wojcik,E. M.Virchows Archiv 2006 ;449(3):302-307
The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population.Malaeb,B. S.; Martin,D. J.; Littooy,F. N.; Lotan,Y.; Waters,W. B.; Flanigan,R. C.; Koeneman,K. S.BJU INTERNATIONAL 2005 ;95(7):977-981
Soluble heparin-binding epidermal growth factor as a predictor for bladder transitional carcinomaVoelzke,B. B.; Fitzgerald,M. P.; McGuire,S. O.; Quek,M. L.; Turk,T. M. T.; Hejna,M. J.; Flanigan,R. C.Society of Urologic Cancer/National Cancer Institute Winter Meeting 2005 ; ( ):
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.Van Veldhuizen,P. J.; Faulkner,J. R.; Lara,P. N.,Jr; Gumerlock,P. H.; Goodwin,J. W.; Dakhil,S. R.; Gross,H. M.; Flanigan,R. C.; Crawford,E. D.Cancer Chemotherapy & Pharmacology 2005 ;56(1):39-45
Risk assessment for occult malignancy in the prostate before radical cystectomy.Kefer,J. C.; Voelzke,B. B.; Flanigan,R. C.; Wojcik,E. M.; Waters,W. B.; Campbell,S. C.UROLOGY 2005 ;66(6):1251-1255
Does lymphadenectomy improve cancer-specific survival in patients with renal cell carcinoma?.Flanigan,R. C.NATURE CLINICAL PRACTICE UROLOGY 2005 ;2(12):588-589
Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System.Cao,Y.; Paner,G. P.; Perry,K. T.; Flanigan,R. C.; Campbell,S. C.; Picken,M. M.ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 2005 ;129(4):487-491
The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function.Mulhall,J.; Land,S.; Parker,M.; Waters,W. B.; Flanigan,R. C.JOURNAL OF SEXUAL MEDICINE 2005 ;2(4):532-540
The prevalence and nature of orgasmic dysfunction after radical prostatectomy.Barnas,J. L.; Pierpaoli,S.; Ladd,P.; Valenzuela,R.; Aviv,N.; Parker,M.; Waters,W. B.; Flanigan,R. C.; Mulhall,J. P.BJU INTERNATIONAL 2004 ;94(4):603-605
Metastatic juxtaglomerular cell tumor in a 52-year-old man.Duan,X.; Bruneval,P.; Hammadeh,R.; Fresco,R.; Eble,J. N.; Clark,J. I.; Vigneswaran,W. T.; Flanigan,R. C.; Picken,M. M.AMERICAN JOURNAL OF SURGICAL PATHOLOGY 2004 ;28(8):1098-1102
Urethral strictureNovakovic,K.; Flanigan,R. C. 2004 ; ( ):765-768
Cytologic features of recurrent lymphoma involving the urinary bladder.Quinn,A. M.; Flanigan,R. C.; Sienko,A.; Wojcik,E. M.DIAGNOSTIC CYTOPATHOLOGY 2004 ;31(3):185-188
Pathologic quiz case: renal mass in an otherwise healthy man. Epithelioid angiomyolipoma.Rubinas,T. C.; Flanigan,R. C.; Picken,M. M.ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 2004 ;128(1):e19-20
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysisFlanigan,R. C.; Mickisch,G.; Sylvester,R.; Tangen,C.; Van Poppel,H.; Crawford,E. D.JOURNAL OF UROLOGY 2004 ;171(3):1071-1076
Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma.Freeman,V. L.; Meydani,M.; Hur,K.; Flanigan,R. C.CANCER 2004 ;101(12):2744-2754
Renal tumor with overlapping distal nephron morphology and karyotype.Lindgren,V.; Paner,G. P.; Flanigan,R. C.; Clark,J. I.; Campbell,S. C.; Picken,M. M.ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 2004 ;128(11):1274-1278
Renal tumors in young adultsEggener,S. E.; Rubenstein,J. N.; Smith,N. D.; Nadler,R. B.; Kontak,J.; Flanigan,R. C.; Waters,W. B.; Picken,M.; Campbell,S. C.JOURNAL OF UROLOGY 2004 ;171(1):106-110
Cytogenetic analysis of a series of 13 renal oncocytomas.Lindgren,V.; Paner,G. P.; Omeroglu,A.; Campbell,S. C.; Waters,W. B.; Flanigan,R. C.; Picken,M. M.JOURNAL OF UROLOGY 2004 ;171(2 Pt 1):602-604
Debulking nephrectomy in metastatic renal cancerFlanigan,R. C.CLINICAL CANCER RESEARCH 2004 ;10(18 Pt 2):6335S-41S
Renal massFlanigan,R. C. 2004 ; ( ):
Urethral cancerFlanigan,R. C. 2004 ; ( ):675-685
A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high risk of recurrence after nephrectomy for renal cell carcinoma - a preliminary report.Wood,C. G.; Escudier,S.; Gorelov,S.; Hoos,A.; Flanigan,R.JOURNAL OF CLINICAL ONCOLOGY 2004 ; ( ):
Written emotional disclosure buffers the effects of social constraints on distress among cancer patients.Zakowski,S. G.; Ramati,A.; Morton,C.; Johnson,P.; Flanigan,R. C.HEALTH PSYCHOLOGY 2004 ;23(6):555-563
Innovations and challenges in renal cancer: consensus statement from the first international conferenceAtkins,M. B.; Avigan,D. E.; Bukowski,R. M.; Childs,R. W.; Dutcher,J. P.; Eisen,T. G.; Figlin,R. A.; Finke,J. H.; Flanigan,R. C.; George,D. J.; Goldberg,S. N.; Gordon,M. S.; Iliopoulos,O.; Kaelin,W. G.,Jr; Linehan,W. M.; Lipton,A.; Motzer,R. J.; Novick,A. C.; Stadler,W. M.; Teh,B. T.; Yang,J. C.; King,L.CLINICAL CANCER RESEARCH 2004 ;10(18 Pt 2):6277S-81S
Social barriers to emotional expression and their relations to distress in male and female cancer patients.Zakowski,S. G.; Harris,C.; Krueger,N.; Laubmeier,K. K.; Garrett,S.; Flanigan,R. C.; Johnson,P.British Journal of Health Psychology 2003 ;8(Pt 3):271-286
Nephrectomy in metastatic renal cell cancerYonover,P. M.; Sharma,S.; Flanigan,R. C. 2003 ; ( ):
Role of nephrectomy in metastatic kidney cancerYonover,P. M.; Sharma,S. K.; Flanigan,R. C.Cancer Treatment & Research 2003 ;116( ):119-135
Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.Unger,J. M.; LeBlanc,M.; Crowley,J. J.; Grossman,H. B.; Natale,R. B.; Wozniak,A. J.; Berenson,J. R.; List,A. F.; Peters,W. A.,3rd; Flanigan,R. C.; Macdonald,J. S.; Al-Sarraf,M.; Thompson,I. M.; Coltman,C. A.,JrJOURNAL OF CLINICAL ONCOLOGY 2003 ;21(23 Suppl):246s-252s
Metastatic renal cell carcinomaFlanigan,R. C.; Campbell,S. C.; Clark,J. I.; Picken,M. M.Current Treatment Options in Oncology 2003 ;4(5):385-390
Cytoreductive nephrectomy in metastatic renal cancerFlanigan,R. C.Current Urology Reports 2003 ;4(1):36-40
Heat Shock Proteins: Biology and Potential Clinical Application.Flanigan,R. C.Kidney Cancer 2003 ;1(1):19-25
Radical retropubic prostatectomy - what works for meFlanigan,R. C.Contemporary urology 2003 ;15(5):13-17
Role of nephrectomy in metastatic diseaseFlanigan,R. C.; Yonover,P. M. 2003 ; (Chapter 44):
Nephrectomy in metastatic renal cell carcinomaCampbell,S. C.; Flanigan,R. C.; Clark,J. I.Current Treatment Options in Oncology 2003 ;4(5):363-372
Effect of prostatic edema on CT-based postimplant dosimetry.Dogan,N.; Mohideen,N.; Glasgow,G. P.; Keys,K.; Flanigan,R. C.International journal of radiation oncology, biology, physics 2002 ;53(2):483-489
Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function.Mulhall,J. P.; Slovick,R.; Hotaling,J.; Aviv,N.; Valenzuela,R.; Waters,W. B.; Flanigan,R. C.JOURNAL OF UROLOGY 2002 ;167(3):1371-1375
Survival advantage of Interleukin-2 over Interferon Immunotherapy when combine with cytoreductive nephrectomy based on SWOP 8949-matched populations.Pantuck,A. J.; Zisman,A.; Chao,D.; Dorey,F.; Flanigan,R. C.; DeKernion,J. B.; Figlin,R.; Belldegrun,A.JOURNAL OF UROLOGY 2002 ;167(Suppl 1):166
Cancer Control Subgroup 4A - Screening and PreventionGrossman,H. B.; Messing,E.; Flanigan,R. C. 2002 ; ( ):73-75
Role of nephrectomy in metastatic renal cell carcinoma.Flanigan,R. C.; Yonover,P. M.; Campbell,S. C.AUA Update Series 2002 ;21(13):242-248
Radical nephrectomy with MetsFlanigan,R. C.Seminars in urologic oncology 2002 ; ( ):
The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy.Gatenby,R. A.; Gawlinski,E. T.; Tangen,C. M.; Flanigan,R. C.; Crawford,E. D.CANCER RESEARCH 2002 ;62(18):5218-5222
Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study.Whitehead,R. P.; Lew,D.; Flanigan,R. C.; Weiss,G. R.; Roy,V.; Glode,M. L.; Dakhil,S. R.; Crawford,E. D.JOURNAL OF IMMUNOTHERAPY 2002 ;25(4):352-358
Objectives for urology residency educationWein,A. J.; Flanigan,R. C.; Resnick,M. I. 2001 ; ( ):
Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group studySchroder,L. E.; Lew,D.; Flanigan,R. C.; Eisenberger,M. A.; Seay,T. E.; Hammond,N.; Needles,B. M.; Crawford,E. D.Urologic oncology 2001 ;6(4):145-148
Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice.Ellis,T. M.; Moser,M. T.; Le,P. T.; Flanigan,R. C.; Kwon,E. D.International immunology 2001 ;13(4):553-558
The role of radical nephrectomy in metastatic renal cell carcinomaFlanigan,R. C.; Yonover,P. M.Seminars in urologic oncology 2001 ;19(2):98-102
The role of resection for patients with renal carcinomaFlanigan,R. C.; Yonover,P. M.Current oncology reports 2001 ;3(5):424-432
Assessing the effect of fatty acids on prostate carcinogenesis in humans: does self-reported dietary intake rank prostatic exposure correctly?.Freeman,V. L.; Meydani,M.; Yong,S.; Pyle,J.; Durazo-Arvizu,R. A.; Liao,Y.; Flanigan,R. C.; Waters,W. B.AMERICAN JOURNAL OF CLINICAL NUTRITION 2001 ;73(4):815-820
Neoplastic disease of the pelvis, ureter, bladder and urethraFlanigan,R. C.; Kim,F. 2001 ; (Chapter 54, Pt. 2):1050-1058
Renal and ureteric tumorsFlanigan,R. C.; Kim,F. 2001 ; (Chapter 24):347-361
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.Flanigan,R. C.; Salmon,S. E.; Blumenstein,B. A.; Bearman,S. I.; Roy,V.; McGrath,P. C.; Caton,J. R.,Jr; Munshi,N.; Crawford,E. D.NEW ENGLAND JOURNAL OF MEDICINE 2001 ;345(23):1655-1659
Is a 1-CM margin necessary during nephron-sparing surgery for renal cell carcinoma?.Piper,N. Y.; Bishoff,J. T.; Magee,C.; Haffron,J. M.; Flanigan,R. C.; Mintiens,A.; Van Poppel,H. P.; Thompson,I. M.; Harmon,W. J.UROLOGY 2001 ;58(6):849-852
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.Mercader,M.; Bodner,B. K.; Moser,M. T.; Kwon,P. S.; Park,E. S.; Manecke,R. G.; Ellis,T. M.; Wojcik,E. M.; Yang,D.; Flanigan,R. C.; Waters,W. B.; Kast,W. M.; Kwon,E. D.Proceedings of the National Academy of Sciences of the United States of America 2001 ;98(25):14565-14570
Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.Catalona,W. J.; Partin,A. W.; Slawin,K. M.; Naughton,C. K.; Brawer,M. K.; Flanigan,R. C.; Richie,J. P.; Patel,A.; Walsh,P. C.; Scardino,P. T.; Lange,P. H.; deKernion,J. B.; Southwick,P. C.; Loveland,K. G.; Parson,R. E.; Gasior,G. H.UROLOGY 2000 ;55(3):372-376
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.Catalona,W. J.; Southwick,P. C.; Slawin,K. M.; Partin,A. W.; Brawer,M. K.; Flanigan,R. C.; Patel,A.; Richie,J. P.; Walsh,P. C.; Scardino,P. T.; Lange,P. H.; Gasior,G. H.; Loveland,K. G.; Bray,K. R.UROLOGY 2000 ;56(2):255-260
Renal cell carcinoma with metastasis to the thyroid glandPitale,S. U.; Sizemore,G. W.; Bakhos,R.; DeJong,S. A.; Flanigan,R. C.; Emanuele,N. V.Urologic oncology 2000 ;5(4):173-175
Prostate cancer - localized (T1, T2)Flanigan,R. C.; Kim,F. J. 2000 ; ( ):410-411
Primary localized amyloidosis of the ureter and bladder managed by ileal interposition.Hafron,J. M.; Flanigan,R. C.Techniques in urology 2000 ;6(1):50-52
The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection.Gao,X.; Mohideen,N.; Flanigan,R. C.; Waters,W. B.; Wojcik,E. M.; Leman,C. R.JOURNAL OF UROLOGY 2000 ;164(6):1982-1986
Comparative analysis of DNA flow cytometry and cytology of bladder washings: review of discordant cases.Bakhos,R.; Shankey,T. V.; Flanigan,R. C.; Fisher,S.; Wojcik,E. M.DIAGNOSTIC CYTOPATHOLOGY 2000 ;22(2):65-69
Bacillus Calmette-Guerin. Is monthly maintenance an option for transitional cell carcinoma of the bladder?Flanigan,R. C.; DeLaurentis,D. A.; Waters,W. B.; Kunz,K.Urologic oncology 2000 ;6(1):16-19
Prostatic levels of fatty acids and the histopathology of localized prostate cancer.Freeman,V. L.; Meydani,M.; Yong,S.; Pyle,J.; Flanigan,R. C.; Waters,W. B.; Wojcik,E. M.JOURNAL OF UROLOGY 2000 ;164(6):2168-2172
Individualization of maintenance immunosuppressive therapy equalizes acute rejection risk in African American versus non-African American renal allograft recipientsBurns,T.; Coutee,J.; Swies,G.; Hatch,D. A.; Holt,D.; Brems,J.; Flanigan,R. C.; Susskind,B.; Lewis,R.TRANSPLANTATION 2000 ;163(4 Supplement):312
Renal massFlanigan,R. C. 2000 ; ( ):292-293
Cytoreduction nephrectomy in metastatic renal cancer: the results of the southwest oncology group trial 8949Flanigan,R. C.; Blumenstein,B.; Salmon,S.; Crawford,D.Proceedings of the American Society of Clinical Oncology 2000 ; (19):abstract 3
Open prostatectomy for benign diseaseKim,F.; Nicholson,B.; Flanigan,R. C. 2000 ; (Chapter 65):600-606
Bladder cancer - TCC, Invasive (T2/3/4)Kim,F. J.; Flanigan,R. C. 2000 ; (Section II):222-223
Should radical nephrectomy be performed in the face of surgically incurable disease?Yonover,P. M.; Flanigan,R. C.CURRENT OPINION IN UROLOGY 2000 ;10(5):429-434
Transrectal ultrasound of the prostate bed after collagen injection.Salomon,C. G.; Dudiak,C. M.; Pyle,J. M.; Wheeler,J. S.; Waters,W. B.; Flanigan,R. C.JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY 1996 ;20(2):279-282
Impact of soy isoflavones on prostate cancer proliferation and apotosis: pilot dataFlanigan,R. C.; Shankey,T. V.; Wojcik,E.; Creech,S.; Waters,W. B.; Campbell,S. C.; Fairbanks,T. ; ( ):
Time from clinical diagnosis to surgery and risk of extracapsular disease in men with clinically localized prostate cancer.Freeman,V. L.; Campbell,K.; Gallagher,K.; Hur,K.; Flanigan,R. C. ; ( ):
Renal tumors in young adults.Eggener,S. E.; Rubenstein,J. R.; Smith,N. D.; Flanigan,R. C.; Campbell,S. C. ; ( ):
Prostatic unsaturated fatty acid levels in patients with clinically localized prostate cancer and risk of biochemical recurrence following prostatectomy. Presented at the 28th Congress of the Societe International DÂ’Urologie (SIU)Flanigan,R. L.; Freeman,V. L.; Meydani,M. ; ( ):
Comparison of ileal neobladder, continent catheterizable pouch, and ilial conduit urinary diversions with respect to complicationsFlanigan,R. C. ; ( ):
Cytoreducation nephrectomy in metastatic renal cancerFlanigan,R. C. ; ( ):
Cytoreduction nephrectomy in metastatic renal cancer: the results of southwest oncology group trial 8949Flanigan,R. C. ; ( ):
Cytoreduction nephrectomy in metastatic renal cancer: the results of the southwest oncology group trial 8949Flanigan,R. C. ; ( ):
Desirability and feasibility of general surgery in urologic trainingFlanigan,R. C. ; ( ):
Does the current TNM system adequately predict recurrence and follow-up practice for stage T1 renal cancers?Flanigan,R. C. ; ( ):
Fatty acid correlates with locally advanced prostate cancerFlanigan,R. C. ; ( ):
Immunotherapy (APC8015) for androgen independent prostate cancer (APC): provenge survival data from a phase 3 randomized placebo-controlled trialFlanigan,R. C. ; ( ):
Kidney cancer uroflow of knowledgeFlanigan,R. C. ; ( ):
Maintenance of certificationFlanigan,R. C. ; ( ):
Management of advanced prostate cancerFlanigan,R. C. ; ( ):
Management of metastatic renal cell carcinoma and partial vs radical nephrectomy perspectives in urologyFlanigan,R. C. ; ( ):
Metastatic RCC: Timing of NephrectomyFlanigan,R. C. ; ( ):
The number of lymph nodes removed at cystectomy is association with the pattern of recurrence of patients with transitional cell cancer after cystectomyFlanigan,R. C. ; ( ):
Possible role of post-operative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomyFlanigan,R. C. ; ( ):
Pre-biopsy serum PSA and highest biopsy Gleason score remain significant predictors of extra-capsular extension: a study of radical prostatectomies over a 5-year periodFlanigan,R. C. ; ( ):
Predictors of survival in advanced renal cancer: results of SWOG trial 8949Flanigan,R. C. ; ( ):
Prognostic factors for biochemical control after radiation therapy following radical prostatectomyFlanigan,R. C. ; ( ):
The relationship between extent of lymphadenectomy and site of recurrence of bladder cancer after cystectomyFlanigan,R. C. ; ( ):
Renal cancer, the good, the bad, and the uglyFlanigan,R. C. ; ( ):
Targeted therapy in renal cancerFlanigan,R. C. ; ( ):
The US perspective on scope of practice and systemic therapyFlanigan,R. C. ; ( ):
Worldwide certification and recertificationFlanigan,R. C. ; ( ):
Prostascint scan in the assessment of patients who undergo radiation therapy for rising PSA after radical prostatectomy.Nagda,S. N.; Mohideen,N.; Flanigan,R. C.; Campbell,S. C.; Khan,U.; Lo,S.; Dillehay,G.; Wagner,R. ; ( ):
Prognostic factors for biochemical control after radiation therapy following prostatectomyFlanigan,R. C. ; ( ):
Glucose-regulated protein-78 (GRP78) expression in bladder cancer: a potential marker for chemotherapy resistanceGorbonos,A.; Knesek,M.; Barkan,G. A.; Paner,G. P.; Woods,M.; Flanigan,R. C.; Quek,M. L. ; ( ):
Bladder cancer outcomes with BCG immunotherapy and cystectomySondej,T. S.; Manganiello,M.; Kadow,B. T.; Flanigan,R. C.; Quek,M. L. ; ( ):
Education
Medical School
Case Western Reserve University School of Medicine
Residency
University Hospitals of Cleveland/Case Western Reserve University, Urology